248 related articles for article (PubMed ID: 20629988)
1. Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications.
Cakir M; Dworakowska D; Grossman A
J Cell Mol Med; 2010 Nov; 14(11):2585-91. PubMed ID: 20629988
[No Abstract] [Full Text] [Related]
2. Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.
Cakir M; Dworakowska D; Grossman A
J Cell Mol Med; 2010 Nov; 14(11):2570-84. PubMed ID: 20629989
[TBL] [Abstract][Full Text] [Related]
3. Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms.
Gatto F; Barbieri F; Arvigo M; Thellung S; Amarù J; Albertelli M; Ferone D; Florio T
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412614
[TBL] [Abstract][Full Text] [Related]
4. Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor.
Luo P; Zhang L; Yang L; An Z; Tan H
Front Endocrinol (Lausanne); 2020; 11():580264. PubMed ID: 33329389
[TBL] [Abstract][Full Text] [Related]
5. The tumour microenvironment of pituitary neuroendocrine tumours.
Marques P; Grossman AB; Korbonits M
Front Neuroendocrinol; 2020 Jul; 58():100852. PubMed ID: 32553750
[TBL] [Abstract][Full Text] [Related]
6. Targeting the somatostatin receptor in pituitary and neuroendocrine tumors.
Veenstra MJ; de Herder WW; Feelders RA; Hofland LJ
Expert Opin Ther Targets; 2013 Nov; 17(11):1329-43. PubMed ID: 23991721
[TBL] [Abstract][Full Text] [Related]
7. The continuing evolution of somatostatin receptor imaging in neuroendocrine tumours.
Navalkissoor S; Buscombe JR
Nucl Med Commun; 2011 Mar; 32(3):163-7. PubMed ID: 21266901
[No Abstract] [Full Text] [Related]
8. A Somatostatin Receptor Subtype-3 (SST
Vázquez-Borrego MC; Gupta V; Ibáñez-Costa A; Gahete MD; Venegas-Moreno E; Toledano-Delgado Á; Cano DA; Blanco-Acevedo C; Ortega-Salas R; Japón MA; Barrera-Martín A; Vasiljevic A; Hill J; Zhang S; Halem H; Solivera J; Raverot G; Gálvez MA; Soto-Moreno A; Paez-Pereda M; Culler MD; Castaño JP; Luque RM
Clin Cancer Res; 2020 Feb; 26(4):957-969. PubMed ID: 31624102
[TBL] [Abstract][Full Text] [Related]
9. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.
Kwekkeboom DJ; Krenning EP; Scheidhauer K; Lewington V; Lebtahi R; Grossman A; Vitek P; Sundin A; Plöckinger U; ;
Neuroendocrinology; 2009; 90(2):184-9. PubMed ID: 19713709
[No Abstract] [Full Text] [Related]
10. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography.
Schaer JC; Waser B; Mengod G; Reubi JC
Int J Cancer; 1997 Mar; 70(5):530-7. PubMed ID: 9052751
[TBL] [Abstract][Full Text] [Related]
11. Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy.
Hu Y; Ye Z; Wang F; Qin Y; Xu X; Yu X; Ji S
Front Endocrinol (Lausanne); 2021; 12():679000. PubMed ID: 34093445
[TBL] [Abstract][Full Text] [Related]
12. From Pituitary Adenoma to Pituitary Neuroendocrine Tumors: How Molecular Pathways may Impact the Therapeutic Management?
Chiloiro S; De Marinis L
Endocr Metab Immune Disord Drug Targets; 2021; 21(10):1744-1759. PubMed ID: 34425741
[TBL] [Abstract][Full Text] [Related]
13. Role of Somatostatin Signalling in Neuroendocrine Tumours.
Rogoza O; Megnis K; Kudrjavceva M; Gerina-Berzina A; Rovite V
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163374
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin-receptor mediated diagnosis and treatment in gastrointestinal neuroendocrine tumours (GEP-NET's).
Oberg K
Rocz Akad Med Bialymst; 2005; 50():62-8. PubMed ID: 16358941
[No Abstract] [Full Text] [Related]
15. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.
Hope TA; Bergsland EK; Bozkurt MF; Graham M; Heaney AP; Herrmann K; Howe JR; Kulke MH; Kunz PL; Mailman J; May L; Metz DC; Millo C; O'Dorisio S; Reidy-Lagunes DL; Soulen MC; Strosberg JR
J Nucl Med; 2018 Jan; 59(1):66-74. PubMed ID: 29025982
[No Abstract] [Full Text] [Related]
16. A specific antibody to detect transcription factor T-Pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours.
Sjöstedt E; Bollerslev J; Mulder J; Lindskog C; Pontén F; Casar-Borota O
Acta Neuropathol; 2017 Oct; 134(4):675-677. PubMed ID: 28823042
[No Abstract] [Full Text] [Related]
17. Lower
Tjörnstrand A; Casar-Borota O; Heurling K; Schöll M; Gjertsson P; Himmelman J; Itsenko O; Ragnarsson O; Filipsson Nyström H
Clin Endocrinol (Oxf); 2020 Mar; 92(3):222-231. PubMed ID: 31868239
[TBL] [Abstract][Full Text] [Related]
18. Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.
Kaemmerer D; Peter L; Lupp A; Schulz S; Sänger J; Prasad V; Kulkarni H; Haugvik SP; Hommann M; Baum RP
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1659-68. PubMed ID: 21626438
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor imaging with (111)In-pentetreotide in gastro-intestinal tract and lung neuroendocrine tumors-Impact on targeted treatment.
Gerasimou G; Moralidis E; Gotzamani-Psarrakou A
Hell J Nucl Med; 2010; 13(2):158-62. PubMed ID: 20808990
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin and somatostatin receptors: from basic concepts to clinical applications.
De Martino MC; Hofland LJ; Lamberts SW
Prog Brain Res; 2010; 182():255-80. PubMed ID: 20541669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
